Clinical Trial Source Dba BTC Network LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$6,600	1
2023	Research	$337,171	15
2022	Research	$532,364	65
2021	Research	$11,126,419	150
2020	Research	$2,974,229	40

Breakdown

Who paid Research payments · program years 2020–2024

Regeneron Pharmaceuticals, Inc. $14,147,058 167 payments
Mylan Inc. $306,288 10 payments
Ucb SA $263,165 28 payments
Mylan Technologies Inc. $117,093 48 payments
Amgen Inc. $78,369 5 payments
ALK-Abello, Inc $51,451 7 payments
Genentech, Inc. $6,759 5 payments
Sumitomo Pharma America, Inc. $6,600 1 payment

Studies the money was for Research payments · program years 2020–2024

A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $12,301,636 115 payments
A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $1,656,405 29 payments
Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $306,288 10 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $166,018 18 payments
Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $117,093 48 payments
A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $94,472 13 payments
Multicenter, Randomized, Parallel Group, Double Blind, Placebo-Controlled (12 17 Years) Including A Single Open Label Arm (6 11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Stu $59,447 3 payments
Mt-11 $51,451 7 payments
ABP 654 P3 PsO Study $51,399 2 payments
A Phase 3, Multicenter, Randomized, Double-Blind Study With A 24-Week Active-Controlled Initial Treatment Period Followed By A 32-Week, Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy $40,761 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.